You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TGR-1202

Showing 26 - 50 of 50
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Ublituximab, Umbralisib, Bendamustine)

Terminated
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
Jul 20, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine

Suspended
  • Grade 1 Follicular Lymphoma
  • +4 more
  • Bendamustine Hydrochloride
  • +13 more
  • Anchorage, Alaska
  • +422 more
Feb 2, 2023

Bladder Cancer Trial in Melbourne (APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending

Not yet recruiting
  • Bladder Cancer
  • APL-1202 and APL-1501 (Single ascending dose)
  • APL-1202 and APL-1501 (Multiple Ascending dose)
  • Melbourne, Victoria, Australia
    Nucleus Network Pty Ltd
Sep 11, 2023

Advanced Solid Tumor Trial in Shanghai (DB-1202)

Not yet recruiting
  • Advanced Solid Tumor
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 29, 2023

Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202 in combination with Epirubicin, Placebo in combination with

Active, not recruiting
  • Non-muscle Invasive Bladder Cancer
  • APL-1202 in combination with Epirubicin
  • Placebo in combination with Epirubicin
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 21, 2022

Muscle Invasive Bladder Cancer Trial in New York, Shanghai (APL-1202 in combination with tislelizumab, Tislelizumab alone)

Recruiting
  • Muscle Invasive Bladder Cancer
  • APL-1202 in combination with tislelizumab
  • Tislelizumab alone
  • New York, New York
  • +1 more
Feb 21, 2022

Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202, Epirubicin Hydrochloride)

Recruiting
  • Non-muscle Invasive Bladder Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 21, 2022

IPF Trial in Istanbul (Telerehabilitation exercise program, Videobased exercise program)

Recruiting
  • IPF
  • Telerehabilitation exercise program
  • Videobased exercise program
  • Istanbul, Zeytinburnu, Turkey
    Yedikule Chest Disease Hospital
Jan 22, 2022

Tumor Growth Rate Predicts Clinical Outcomes for Advanced

Recruiting
  • Non-Small Cell Lung Cancer
  • This item is not applicable to our observational study.
  • Guangzhou, Guangdong, China
  • +2 more
Mar 15, 2021

Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia Trial

Not yet recruiting
  • Chronic Graft-versus-Host-Disease
  • +4 more
    • (no location specified)
    Jan 11, 2023

    Bladder Cancer Trial in Randwick (APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2, APL-1501 ER Tablets 3+APL-1202+APL-1501

    Completed
    • Bladder Cancer
    • APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
    • APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2
    • Randwick, New South Wales, Australia
      Scientia clinical research
    Jun 25, 2021

    Non Cystic Fibrosis Bronchiectasis Trial in Worldwide (Ciprofloxacin dispersion for inhalation, Placebo)

    Completed
    • Non Cystic Fibrosis Bronchiectasis
    • Ciprofloxacin dispersion for inhalation
    • Placebo
    • Phoenix, Arizona
    • +94 more
    Mar 23, 2021

    Breast Cancer Trial in United States (The Gamma Pod, CT simulation)

    Completed
    Has Results
    • Breast Cancer
    • The Gamma Pod
    • CT simulation
    • Baltimore, Maryland
    • +3 more
    Jan 5, 2022

    Non-muscle Invasive Bladder Cancer Trial (APL-1202 treatment)

    Completed
    • Non-muscle Invasive Bladder Cancer
    • APL-1202 treatment
    • (no location specified)
    Aug 12, 2020

    Non-Muscle Invasive Bladder Cancer (NMIBC) Trial in New York, Myrtle Beach (APL-1202)

    Completed
    • Non-Muscle Invasive Bladder Cancer (NMIBC)
    • New York, New York
    • +1 more
    Jul 16, 2020

    Allogeneic Hematopoietic Stem Cell Transplantation Trial in United States

    Completed
    Has Results
    • Allogeneic Hematopoietic Stem Cell Transplantation
      • Phoenix, Arizona
      • +41 more
      Dec 5, 2018

      Liver Metastases of Small Intestinal Neuroendocrine Tumors.

      Unknown status
      • Neuroendocrine Tumors
      • Liver Metastases
      • Volumetric measurements of liver metastases
      • Lyon, France
        Service de radiologie-Pavillon B-Cellule Recherche imagerie - Hô
      Sep 26, 2018

      Healthy Trial in Lincoln (AC-1202, AC-SD-01 (50 g), AC-SD-01 (75 g))

      Completed
      • Healthy
      • Lincoln, Nebraska
        Celerion
      Jun 26, 2017

      Healthy Trial in Tempe (AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®)

      Completed
      • Healthy
      • AC-1204 mixed in water
      • +2 more
      • Tempe, Arizona
        Celerion
      Apr 10, 2017

      Healthy Trial in Tempe (Caprylic Triglyceride Oil, AC-1202, Axona)

      Completed
      • Healthy
      • Caprylic Triglyceride Oil
      • +3 more
      • Tempe, Arizona
        Celerion, Inc
      Apr 10, 2017

      COPD Trial in Santa Cruz do Sul (Inspiratory Muscle Training, Pulmonary Rehabilitation)

      Completed
      • Chronic Obstructive Pulmonary Disease
      • Inspiratory Muscle Training
      • Pulmonary Rehabilitation
      • Santa Cruz do Sul, Rio Grande do Sul, Brazil
        Universidade de Santa Cruz do Sul
      Apr 24, 2017

      Alzheimer Trial in Los Angeles (caprylidene, Placebo)

      Completed
      • Alzheimer Disease
      • caprylidene
      • Placebo
      • Los Angeles, California
      • +1 more
      Mar 19, 2015

      Healthy Trial (BIBF 1120 ES)

      Completed
      • Healthy
      • BIBF 1120 ES
      • (no location specified)
      Jul 17, 2014

      Type 2 Diabetes, Chronic Liver Disease Trial in Kanazawa (UDCA, Sitagliptin)

      Unknown status
      • Type 2 Diabetes Mellitus
      • Chronic Liver Disease
      • Kanazawa, Ishikawa, Japan
        Internal medicine, Kanazawa university hospital
      Apr 15, 2011

      Three Formulations of Ketasyn Administered for 14 Days in

      Completed
      • Alzheimer's Disease
      • Ketasyn
      • St. Petersburg, Florida
        Meridien Research Center
      Oct 7, 2008